Review/drug metabolism and transport: P-glycoprotein: So many ways to turn it on

Journal of Clinical Pharmacology

Volumn 48, Issue 3, 2008, Pages 365-378

  Callaghan, Richard ^a   Crowley, Emily ^a   Potter, Simon ^b   Kerr, Ian D ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ABCB1; Chemotherapy; Drug absorption; Drug elimination; Drug resistance; P glycoprotein

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CELL NUCLEUS RECEPTOR; CYCLOSPORIN A; CYTOCHROME P450; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DILTIAZEM; DOCETAXEL; DOXORUBICIN; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; ETOPOSIDE DERIVATIVE; GLUCOSE; GLYCOPROTEIN P; HYDROCORTISONE; MITOMYCIN C; MORPHINE; NIFEDIPINE; PACLITAXEL; PLATINUM COMPLEX; PROGESTERONE; QUINIDINE; REACTIVE OXYGEN METABOLITE; RIFAMPICIN; TRABECTEDIN; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE; CYTOCHROME P450 3A;

BIOENERGY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL INFILTRATION; CELL STRESS; DRUG ABSORPTION; DRUG ELIMINATION; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; GENE EXPRESSION; HYPOXIA; IONIZING RADIATION; MACROPHAGE; MOLECULAR MECHANICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RADIATION INJURY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR; ANIMAL; BIOLOGICAL MODEL; DRUG RESISTANCE; HUMAN; METABOLISM;

ANIMALS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; SIGNAL TRANSDUCTION;

EID: 39149089608     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007311568     Document Type: Review

References (158)

1. Callaghan R., Ford RC, Kerr ID The translocation mechanism of P-glycoprotein. FEBS Lett. 2006 ; 580: 1056-1063.
2. Ambudkar SV, Kim IW, Sauna ZE The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci. 2006 ; 27: 392-400.
3. Gottesman MM, Fojo T., Bates SE Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002 ; 2: 48-58.
4. Cordon-Cardo C., O'Brien JP, Casals D., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989 ; 86: 695-698.
5. Cordon-Cardo C., O'Brien JP, Boccia J., et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990 ; 38: 1277-1287.
6. Pavelic ZP, Reising J., Pavelic L., et al. Detection of P-glycoprotein with 4 monoclonal antibodies in normal and tumor tissues. Arch Otolaryngol Head Neck Surg. 1993 ; 119: 753-757.
7. Smit JJ, Schinkel AH, Mol CA, et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest. 1994 ; 71: 638-649.
8. Grkovic S., Brown MH, Skurray RA Transcriptional regulation of multidrug efflux pumps in bacteria. Semin Cell Dev Biol. 2001 ; 12: 225-237.
9. Kohno K., Sato S., Takano H., Matsuo K., Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun. 1989 ; 165: 1415-1421.
10. Chaudhary PM, Roninson IB Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993 ; 85: 632-639.
11. Cole SP, Bhardwaj G., Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 ; 258: 1650-1654.
12. Doyle LA, Yang W., Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998 ; 95: 15665-15670.
13. McMahon G. VEGF receptor signalling in tumor angiogenesis. Oncologist. 2000 ; 5 Suppl 1: 3-10.
14. Bernards R., Weinberg RA A progression puzzle. Nature. 2002 ; 418: 823.
15. Shtil AA Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells. Curr Drug Targets. 2001 ; 2: 57-77.
16. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential, and response to therapy of breast cancer. Breast Cancer Res. 2001 ; 3: 323-7.
17. Klaunig JE, Kamendulis LM The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004 ; 44: 239-267.
18. Cook JA, Guis D., Wink DA, et al. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol. 2004 ; 14: 259-266.
19. Szatrowski TP, Nathan CF Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991 ; 51: 794-798.
20. Toyokuni S., Okamoto K., Yodoi J., Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995 ; 358: 1-3.
21. Gabbita SP, Robinson KA, Stewart CA, Floyd RA, Hensley K. Redox regulatory mechanisms of cellular signal transduction. Arch Biochem Biophys. 2000 ; 376: 1-13.
22. Denu JM, Tanner KG Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry. 1998 ; 37: 5633-5642.
23. Kumar S., Rabson AB, Gelinas C. The RxxRxRxxC motif conserved in all Rel/kappa B proteins is essential for the DNA-binding activity and redox regulation of the v-Rel oncoprotein. Mol Cell Biol. 1992 ; 12: 3094-3106.
24. Matthews JR, Wakasugi N., Virelizier JL, Yodoi J., Hay RT Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 1992 ; 20: 3821-3830.
25. Hayashi T., Ueno Y., Okamoto T. Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem. 1993 ; 268: 11380-11388.
26. Kuo MT, Liu Z., Wei Y., et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene. 2002 ; 21: 1945 -1954.
27. Hsu TC, Young MR, Cmarik J., Colburn NH Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med. 2000 ; 28: 1338-1348.
28. Young MR, Li JJ, Rincon M., et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A. 1999 ; 96: 9827-9832.
29. Abate C., Patel L., Rauscher FJ 3 rd, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science. 1990 ; 249: 1157-1161.
30. Janssen YM, Heintz NH, Mossman BT Induction of c-fos and c-jun proto-oncogene expression by asbestos is ameliorated by N-acetyl-L-cysteine in mesothelial cells. Cancer Res. 1995 ; 55: 2085-2089.
31. Dalton TP, Shertzer HG, Puga A. Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol. 1999 ; 39: 67-101.
32. Xie K., Huang S. Regulation of cancer metastasis by stress pathways. Clin Exp Metastasis. 2003 ; 20: 31-43.
33. Ziemann C., Burkle A., Kahl GF, Hirsch-Ernst KI Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis. 1999 ; 20: 407-414.
34. Nwaozuzu OM, Sellers LA, Barrand MA Signalling pathways influencing basal and H2O2-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier. J Neurochem. 2003 ; 87: 1043-1051.
35. Thevenod F., Friedmann JM, Katsen AD, Hauser IA Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem. 2000 ; 275: 1887-1896.
36. Ros JE, Schuetz JD, Geuken M., et al. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology. 2001 ; 33: 1425-1431.
37. Gatenby RA, Gillies RJ Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004 ; 4: 891-899.
38. Helmlinger G., Yuan F., Dellian M., Jain RK Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997 ; 3: 177-182.
39. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997 ; 82: 291-295.
40. Thews O., Gassner B., Kelleher DK, Schwerdt G., Gekle M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia. 2006 ; 8: 143-152.
41. Lee YJ, Galoforo SS, Berns CM, et al. Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. J Biol Chem. 1998 ; 273: 5294-5299.
42. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci. 2000 ; 899: 349-362.
43. Ledoux S., Yang R., Friedlander G., Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res. 2003 ; 63: 7284-7290.
44. Semenza GL Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev. 1998 ; 8: 588-594.
45. Wartenberg M., Ling FC, Muschen M., et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. Faseb J. 2003 ; 17: 503-505.
46. Song X., Liu X., Chi W., et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol. 2006 ; 58: 776-784.
47. Wartenberg M., Ling FC, Scallenberg M., et al. Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem. 2001 ; 276: 17420-17428.
48. Comerford KM, Cummins EP, Taylor CT c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res. 2004 ; 64: 9057-9061.
49. Ueda K., Pastan I., Gottesman MM Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem. 1987 ; 262: 17432-17436.
50. Comerford KM, Wallace TJ, Karhausen J., et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002 ; 62: 3387-3394.
51. Brown NS, Jones A., Fujiyama C., Harris AL, Bicknell, R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000 ; 60: 6298-6302.
52. Felix RA, Barrand MA P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem. 2002 ; 80: 64-72.
53. Krishnamurthy P., et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004 ; 279: 24218-24225.
54. Kundu N., Zhang S., Fulton AM Sublethal oxidative stress inhibits tumor cell adhesion and enhances experimental metastasis of murine mammary carcinoma. Clin Exp Metastasis. 1995 ; 13: 16-22.
55. Fulton AM, Chong YC The role of macrophage-derived TNFa in the induction of sublethal tumor cell DNA damage. Carcinogenesis. 1992 ; 13: 77-81.
56. Corna G., Santambrogio P., Minotti G., Cairo G. Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem. 2004 ; 279: 13738-13745.
57. Schweyer S., Soruri A., Heintze A., Radzun HJ, Fayyazi A. The role of reactive oxygen species in cisplatin-induced apoptosis in human malignant testicular germ cell lines. Int J Oncol. 2004 ; 25: 1671-1676.
58. Wang X., Martindale JL, Liu Y., Holbrook NJ The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J. 1998 ; 333 (Pt 2). 291-300.
59. Davis W. Jr, Ronai Z., Tew KD Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther. 2001 ; 296: 1-6.
60. Yokomizo A., Ono M., Nanri H., et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 1995 ; 55: 4293-4296.
61. Mansat-de Mas V., Bezombes C., Quillet-Mary A., et al. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol. 1999 ; 56: 867-874.
62. Nielsen D., Maare C., Eriksen J., Litman T., Skovsgaard T. Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation. Int J Radiat Oncol Biol Phys. 2001 ; 51: 1050-1057.
63. Hill BT, Whelan RD, Hurst HC, McClean S. Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation. Cancer. 1994 ; 73: 2990-2999.
64. Hill BT, Deuchars K., Hosking LK, Ling V., Whelan RD Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst. 1990 ; 82: 607-612.
65. McClean S., Whelan RD, Hosking LK, et al. Characterization of the P-glycoprotein overexpressing drug resistance phenotype exhibited by Chinese hamster ovary cells following their in vitro exposure to fractionated X-irradiation. Biochim Biophys Acta. 1993 ; 1177: 117-126.
66. Ohga T., Uchiumi T., Makino Y., et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem. 1998 ; 273: 5997-6000.
67. Spitz DR, Azzam EI, Li JJ, Gius D. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev. 2004 ; 23: 311-322.
68. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell. 1995 ; 80: 199-211.
69. Gill PK, Gescher A., Gant TW Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta. Eur J Biochem. 2001 ; 268: 4151-4157.
70. Marks DC, Davey MW, Davey RA, Kidman AD Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem Pharmacol. 1995 ; 50: 475-480.
71. Osborn MT, Berry A., Ruberu MS, et al. Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways. Oncogene. 1999 ; 18: 5756-5764.
72. Yang JM, Vassil AD, Hait WN Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol. 2001 ; 60: 674-680.
73. Vertegaal AC, Kuiperij HB, Yamaoka S., et al. Protein kinase C-alpha is an upstream activator of the IkappaB kinase complex in the TPA signal transduction pathway to NF-kappaB in U2OS cells. Cell Signal. 2000 ; 12: 759-768.
74. Das KC, White CW Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem. 1997 ; 272: 14914-14920.
75. Randle RA, Raguz S., Higgins CF, Yague E. Role of the highly structured 5′-end region of MDR1 mRNA in P-glycoprotein expression. Biochem J. 2007 ; 406: 445-455.
76. Gomez-Martinez, A., et al. Posttranscriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res. 2007 ; 5: 641-653.
77. van der Valk P., van Kalken CK, Ketelaars H., et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol. 1990 ; 1: 56-64.
78. Fromm MF Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004 ; 25: 423-429.
79. Schinkel AH The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997 ; 8: 161-170.
80. Hughes CS, Vaden SL, Manaugh CA, Price GS, Hudson LC Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. J Neurooncol. 1998 ; 37: 45-54.
81. Suzuki H., Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci. 2000 ; 12: 3-12.
82. Schuetz EG, Beck WT, Schuetz JD Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 ; 49: 311-318.
83. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A. 1996 ; 93: 4001-4005.
84. Lan LB, Dalton JT, Schuetz EG Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol. 2000 ; 58: 863-869.
85. Kim RB, Wandel C., Leake B., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 ; 16: 408-414.
86. Wacher VJ, Wu CY, Benet LZ Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995 ; 13: 129-134.
87. Benet LZ, Cummins CL The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev. 2001 ; 50 Suppl 1: S3-11.
88. Hennessy M., Kelleher D., Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002 ; 53: 75-82.
89. Alfaro CL, Piscitelli SC Drug interactions. In: Principles of Clinical Pharmacology Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP (eds). London, England: Academic Press ; 2001: 167-180.
90. von Richter O., Burk O., Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004 ; 75: 172-183.
91. Salphati L., Benet LZ Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol. 1998 ; 55: 387-395.
92. Mills JB, Rose KA, Sadagopan N., Sahi, J., de Morais SM Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther. 2004 ; 309: 303-309.
93. Akiyama TE, Gonzalez FJ Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim Biophys Acta. 2003 ; 1619: 223-234.
94. Chin KV, Tanaka S., Darlington G., Pastan I., Gottesman MM Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem. 1990 ; 265: 221-226.
95. Geick A., Eichelbaum M., Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 ; 276: 14581-14587.
96. Burt RK, Thorgeirsson SS Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst. 1988 ; 80: 1383-1386.
97. Blumberg B., Sabbagh W. Jr, Juguilon H., et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998 ; 12: 3195-3205.
98. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998 ; 102: 1016-1023.
99. Bertilsson G., Heidrich J., Svensson K., et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A. 1998 ; 95: 12208-12213.
100. Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos. 2002 ; 30: 608-612.
101. Mangelsdorf DJ, Thummel C., Beato M., et al. The nuclear receptor superfamily: the second decade. Cell. 1995 ; 83: 835-839.
102. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM Nuclear receptor that identifies a novel retinoic acid response pathway. Nature. 1990 ; 345: 224-229.
103. Kurokawa R., DiRenzo J., Boehm M., et al. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature. 1994 ; 371: 528-531.
104. Forman BM, Umesono K., Chen J., Evans RM Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell. 1995 ; 81: 541-550.
105. Kliewer SA, Umesono K., Noonan DJ, Heyman RA, Evans RM Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992 ; 358: 771-774.
106. Willy PJ, Umesono K., Ong ES, et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995 ; 9: 1033-1045.
107. Giguere V. Orphan nuclear receptors: from gene to function. Endocr Rev. 1999 ; 20: 689-725.
108. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995 ; 83: 841-850.
109. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 ; 383: 728-731.
110. Rudney H., Sexton RC Regulation of cholesterol biosynthesis. Annu Rev Nutr. 1986 ; 6: 245-272.
111. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999 ; 284: 1365-1368.
112. Makishima M., Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999 ; 284: 1362-1365.
113. Chen W., Owsley E., Yang Y., Stroup D., Chiang JY Nuclear receptor-mediated repression of human cholesterol 7alphahydroxylase gene transcription by bile acids. J Lipid Res. 2001 ; 42: 1402-1412.
114. Forman BM, Tzameli I., Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature. 1998 ; 395: 612-615.
115. Huss JM, Wang SI, Astrom A., McQuiddy P., Kasper CB Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. Proc Natl Acad Sci U S A. 1996 ; 93: 4666-4670.
116. Quattrochi LC, Mills AS, Barwick JL, Yockey CB, Guzelian PS A novel cis-acting element in a liver cytochrome P450 3A gene confers synergistic induction by glucocorticoids plus antiglucocorticoids. J Biol Chem. 1995 ; 270: 28917-28923.
117. Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 2001 ; 292: 2329-2333.
118. Ekins S., Erickson JA A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos. 2002 ; 30: 96-99.
119. Ourlin JC, Lasserre F., Pineau T., et al. The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol. 2003 ; 17: 1693-703.
120. Kim H-J., Kim J-Y., Park Y-Y., Choi H-S. Synergistic activation of the human orphan nuclear receptor SHP gene promoter by basic helix-loop-helix protein E2A and orphan nuclear receptor SF-1. Nucl Acids Res. 2003 ; 31: 6860-6872.
121. Lu TT, Makishima M., Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000 ; 6: 507-515.
122. Synold TW, Dussault I., Forman BM The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001 ; 7: 584-590.
123. Bauer B., Hartz AMS, Fricker G., Miller DS. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol. 2004 ; 66: 413-419.
124. Greiner B., Eichelbaum M., Fritz P., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999 ; 104: 147-153.
125. Pfrunder A., Gutmann H., Beglinger C., Drewe J. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol. 2003 ; 55: 59-66.
126. Lamba J., Strom S., Venkataramanan R., et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006 ; 79: 325-338.
127. Markey SP Pathways of drug metabolism. In: Principles of Clinical Pharmacology. Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP (eds). London, England: Academic Press ; 2001: 167-180.
128. Madhu C., Klaassen CD Protective effect of pregnenolone-16 alpha-carbonitrile on acetaminophen-induced hepatotoxicity in hamsters. Toxicol Appl Pharmacol. 1991 ; 109: 305-313.
129. Liu L., Klaassen CD Regulation of hepatic sulfotransferases by steroidal chemicals in rats. Drug Metab Dispos. 1996 ; 24: 854-858.
130. Falkner KC, Pinaire JA, Xiao GH, Geoghegan TE, Prough RA Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol Pharmacol. 2001 ; 60: 611-619.
131. Xie W., Yeuh M-F., Radominska-Pandya A., et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. PNAS. 2003 ; 100: 4150-4155.
132. Maglich JM, Stoltz CM, Goodwin B., Hawkins-Brown D., Moore JT, Kliewer SA Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol. 2002 ; 62: 638-646.
133. Keppler D., Leier I., Jedlitschky G., Konig J. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem Biol Interact. 1998 ; 111-112: 153-161.
134. Homolya L., Varadi A., Sarkadi B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors. 2003 ; 17: 103-114.
135. Hirohashi T., et al. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J Pharmacol Exp Ther. 2000 ; 292: 265-270.
136. Kullak-Ublick GA, Becker MB Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev. 2003 ; 35: 305-317.
137. Kast HR, Goodwin B., Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 ; 277: 2908-2915.
138. Kauffmann HM, Pfannschmidt S., Zoller H., et al. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 ; 171: 137-146.
139. Cherrington NJ, Hartley DP, Li N., Johnson DR, Klaassen CD Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther. 2002 ; 300: 97-104.
140. Sinal CJ, Tohkin M., Miyata M., et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000 ; 102: 731-744.
141. Schuetz EG, Strom S., Yasuda K., et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem. 2001 ; 276: 39411-39418.
142. Panagotopulos SE, Witting SR, Horace EM, Hui DY, Maiorano JN, Davidson WS The role of apolipoprotein A-I helix 10 in apolipoprotein-mediated cholesterol efflux via the ATP-binding cassette transporter ABCA1. J Biol Chem. 2002 ; 277: 39477-39484.
143. Wang N., Silver DL, Thiele C., Tall AR ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001 ; 276: 23742-23747.
144. Smith JD, Le Goff W., Settle M., et al. ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I. J Lipid Res. 2004 ; 45: 635-644.
145. Klett EL, Lee MH, Adams DB, Chavin KD, Patel SB Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder, and intestine. BMC Gastroenterol. 2004 ; 4: 21.
146. Kaneko E., Matsudo M., Yamada Y., et al. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem. 2003 ; 278: 36091-36098.
147. Klett EL, Lu K., Kosters A., et al. A mouse model of sitosterolemia: absence of Abcg8/sterolin-2 results in failure to secrete biliary cholesterol. BMC Med. 2004 ; 2: 5.
148. Duan LP, Wang HH, Wang DQ Cholesterol absorption is mainly regulated by the jejunal and ileal ATP-binding cassette sterol efflux transporters Abcg5 and Abcg8 in mice. J Lipid Res. 2004 ; 45: 1312-1323.
149. Wu JE, Basso F., Shamburek RD, et al. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice. J Biol Chem. 2004 ; 279: 22913-22925.
150. Hazlehurst LA, Landowski TH, Dalton WS Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 2003 ; 22: 7396-7402.
151. Henning T., Kraus M., Brischwein M., Otto AM, Wolf B. Relevance of tumor microenvironment for progression, therapy, and drug development. Anticancer Drugs. 2004 ; 15: 7-14.
152. Galmarini CM, Galmarini FC Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Investig Drugs. 2003 ; 4: 1416-1421.
153. Masuyama H., Hiramatsu Y., Kodama J., Kudo T. Expression and potential roles of pregnane X receptor in endometrial cancer. J Clin Endocrinol Metab. 2003 ; 88: 4446-4454.
154. Dotzlaw H., Leygue E., Watson P., Murphy LC The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin Cancer Res. 1999 ; 5: 2103-2107.
155. Niesor EJ, Flach J., Lopes-Antoni I., Perez A., Bentzen CL The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 ; 7: 231-259.
156. Tsujie M., Nakamori S., Okami J., et al. Growth inhibition of pancreatic cancer cells through activation of peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Int J Oncol. 2003 ; 23: 325-331.
157. Silverman JA, Schrenk D. Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver. Faseb J. 1997 ; 11: 308-313.
158. Raguz S., Tamburo De Bella M., Tripuraneni G., et al. Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res. 2004 ; 10: 2776-2783.